Abstract
Aim
Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists have immunomodulatory and anti-inflammatory effects. The study investigated the autoimmune injuries of diabetic cardiomyopathy (DCM) and tested the hypothesis that PPAR-γ agonists suppress disordered immune responses in diabetic heart, thereby preventing evolution of DCM.
Methods
STZ-induced diabetic rats were assigned to five groups: DM group, given no treatment; INS group, given insulin (4U kg−1 d−1); PIL group, given low dose pioglitazone (4 mg kg−1 d−1); PIL/INS group, given both low dose pioglitazone and insulin; PIH group, given high dose pioglitazone (20 mg kg−1 d−1). Normal rats (CON group) were also monitored as control. The pathologic abnormalities of hearts were observed. The immunoglobulin deposition was examined by immunohistochemistry and immunofluorescence.
Results
At 16 weeks, interstitial fibrosis was shown in diabetic heart which was accompanied by plenty of inflammatory cells infiltrated. Pioglitazone therapy could ameliorate the cardiac injuries. Shown by immunohistochemistry, the difference of integrated optical density (IOD) of immunoglobulin deposition among each group had statistic significance. No obvious immunoglobulins were deposited in the intercellular substance of heart in CON group (IgA 290.8 ± 88.1, IgG 960.4 ± 316.0 and IgM 341.3 ± 67.9). But the deposition of immunoglobulins increased significantly in DM group (IgA 7,047.5 ± 1,328.3, P < 0.05; IgG 28,945.9 ± 5,160.7, P < 0.05 and IgM 8,580.8 ± 1,336.8, P < 0.05). Administration of pioglitazone greatly reduced the increased deposition in a dose-dependent fashion. Moreover, the statistical significance was the same with immunofluorescence analysis as with immunohistochemical examination.
Conclusions
The data suggest that disordered immune responses play an important role in the pathogenesis of DCM. Pioglitazone showed protective effects by inhibiting the immunoglobulin deposition on diabetic myocardium.
Similar content being viewed by others
References
Gao H, Qiu M (2005) More research work should be done on the pathogenesis of autoimmune injuries to the multiple organs in some T2 diabetes Mellitus. Natl Med J China 85:793–795
Qiu M, Meng C (2006) The role of complement activation in the pathogenesis of diabetic complications. Chin J Endocrinol Metab 22:303–305
Meng C, Gao H, Qiu M et al (2006) Immunological injury on the retina in streptozotocin-induced diabetic rats. Chin J Endocrinol Metab 22:588–589
Zhang X, Cui J, Qiu M et al (2008) The effects of cyclosporine A on immunoglobulins deposition in retina of streptozotocin-induced diabetic rats. Chin J Intern Med 47:125–128
Cui J, Zhang P, Qiu M et al (2010) Preventive effects of cyclosporine A on immunoglobulins deposition on heart of STZ-induced diabetic rats. Chin J Diabetes Mellitus 2:142–147
Cui J, Qiu M, Li D et al (2010) The protective effects of cyclosporine A on aortic immunological injuries in STZ-induced diabetic rats. Chin J Cardiol 38:440–444
Pershadsingh HA (2004) Peroxisome proliferator-activated receptor-gamma: therapeutic target for diseases beyond diabetes: quo vadis? Expert Opin Investig Drugs 13:215–228
Lena S, Samir NP, Kodjo A et al (2009) Rosiglitazone modulates innate immune responses to Plasmodium falciparum and improves outcome in experimental cerebral malaria. J Infect Dis 199:1536–1545
Cuzzocrea S, Pisano B, Dugo L et al (2004) Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces acute inflammation. Eur J Pharmacol 483:79–93
Antonelli A, Ferrari SM, Frascerra S et al (2010) CXCL9 and CXCL11 chemokines modulation by peroxisome proliferator-activated receptor-alpha agonists secretion in Graves’ and normal thyrocytes. J Clin Endocrinol Metab 95:E413–E420
Klotz L, Schmidt M, Giese T et al (2005) Proinflammatory stimulation and pioglitazone treatment regulate peroxisome proliferator-activated receptor gamma levels in peripheral blood mononuclear cells from healthy controls and multiple sclerosis patients. J Immunol 175:4948–4955
Von Knethen A, Brune B (2002) Activation of peroxisome proliferator activated receptor γ by nitric oxide in monocytes/macrophages down-regulates p47phox and attenuates the respiratory burst. J Immunol 169:2619–2626
Faine LA, Rudnicki M, César FA et al (2011) Anti-inflammatory and antioxidant properties of a new arylidene-thiazolidinedione in macrophages. Curr Med Chem 18:3351–3360
Choi JM, Bothwell AL (2012) The nuclear receptor PPARs as important regulators of T-cell functions and autoimmune diseases. Mol Cells 33:217–222
Cunard R, Eto Y, Muljadi JT et al (2004) Repression of IFN-γ expression by peroxisome proliferator-activated receptor γ. J Immunol 172:7530–7536
Housley WJ, Adams CO, Vang AG et al (2011) Peroxisome proliferator-activated receptor gamma is required for CD4 + T cell-mediated lymphopenia-associated autoimmunity. J Immunol 187:4161–4169
Yanagita M, Kobayashi R, Kojima Y et al (2012) Nicotine modulates the immunological function of dendritic cells through peroxisome proliferator-activated receptor-γ upregulation. Cell Immunol 274:26–33
Niino M (2007) Peroxisome proliferator-activated receptor agonists as potential therapeutic agents in multiple sclerosis. Mini Rev Med Chem 7:1129–1135
Peiris M, Monteith GR, Roberts-Thomson SJ et al (2007) A model of experimental autoimmune encephalomyelitis (EAE) in C57BL/6 mice for the characterisation of intervention therapies. J Neurosci Methods 163:245–254
Hasegawa H, Takano H, Zou Y et al (2005) Pioglitazone, a peroxisome proliferator-activated receptor gamma activator, ameliorates experimental autoimmune myocarditis by modulating Th1/Th2 balance. J Mol Cell Cardiol 38:257–265
Yuan Z, Liu Y, Zhang J et al (2005) Cardioprotective effects of peroxisome proliferator activated receptor c activators on acute myocarditis: anti-inflammatory actions associated with nuclear factor κB blockade. Heart 91:1203–1208
Demerjian M, Man MQ, Choi EH et al (2006) Topical treatment with thiazolidinediones, activators of peroxisome proliferator-activated receptor-gamma, normalizes epidermal homeostasis in a murine hyperproliferative disease model. Exp Dermatol 15:154–160
Pershadsingh HA, Benson SC, Ellis CN (2005) Improvement in psoriasis with rosiglitazone in a diabetic and a nondiabetic patient. Skin med 4:386–390
Schaefer KL, Denevich S, Ma C et al (2005) Intestinal antiinflammatory effects of thiazolidinedione peroxisome proliferator-activated receptor-gamma ligands on T helper type 1 chemokine regulation include nontranscriptional control mechanisms. Inflamm Bowel Dis 11:244–252
Buckingham RE (2005) Thiazolidinediones: pleiotropic drugs with potent anti-inflammatory properties for tissue protection. Hepatol Res 33:167–170
Pickup JC (2004) Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 27:813–823
Donath MY, Storling J, Maedler K et al (2003) Inflammatory mediators and islet beta-cell failure. A link between type 1 and type 2 diabetes. J Mol Med 81:455–470
Gale EAM (2006) Declassifying diabetes. Diabetologia 49:1989–1995
Kurien BT, Scofield RH (2008) Autoimmunity and oxidatively modified autoantigens. Autoimmun Rev 7:567–573
Kurien BT, Hensley K, Bachmann M et al (2006) Oxidatively modified autoantigens in autoimmune diseases. Free Radic Biol Med 41:549–556
Ahmed N, Babaei-Jadidi R, Howell SK et al (2005) Degradation products of proteins damaged by glycation, oxidation and nitration in clinical type 1 diabetes. Diabetologia 48:1590–1603
Wang G, Li H, Firoze Khan M (2012) Differential oxidative modification of proteins in MRL+/+ and MRL/lpr mice: increased formation of lipid peroxidation-derived aldehyde-protein adducts may contribute to accelerated onset of autoimmune response. Free Radic Res 46:1472–1481
Tam LS, Shang Q, Li EK et al (2013) Serum soluble receptor for advanced glycation end products levels and aortic augmentation index in early rheumatoid arthritis-a prospective study. Semin Arthritis Rheum 42:333–345
Speidl WS, Kastl SP, Huber K et al (2011) Complement in atherosclerosis: friend or foe? J Thromb Haemost 9:428–440
Fosbrink M, Niculescu F, Rus V et al (2006) C5b-9-induced endothelial cell proliferation and migration are dependent on Akt inactivation of forkhead transcription factor FOXO1. J Biol Chem 281:19009–19018
Raquel H, William TH, Montse C et al (2011) Immunoregulatory mechanisms of macrophage PPAR γ in mice with experimental inflammatory bowel disease. Mucosal Immunol 4:304–313
Zhang W, Eric AS, Paska AP et al (2008) Pioglitazone inhibits the expression of inflammatory cytokines from both monocytes and lymphocytes in patients with impaired glucose tolerance. Arterioscler Thromb Vasc Biol 28:2312–2318
Gao M, Hu Z, Zheng Y et al (2011) Peroxisome proliferator-activated receptor γ agonist troglitazone inhibits high mobility group box 1 expression in endothelial cells via suppressing transcriptional activity of nuclear factor κB and activator protein 1. Shock 36:228–234
Chen J, Mehta JL (2006) Angiotensin II-mediated oxidative stress and procollagen-1 expression in cardiac fibroblasts: blockade by pravastatin and pioglitazone. Am J Physiol Heart Circ Physiol 291:H1738–H1745
Ti Y, Hao MX, Li CB et al (2011) Rosiglitazone attenuates myocardial remodeling in spontaneously hypertensive rats. Hypertens Res 34:354–360
Straus DS, Glass CK (2007) Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. Trends Immunol 28:551–558
Chawla A, Barak Y, Nagy L et al (2001) PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med 7:48–52
Lee JH, Woo JH, Woo SU et al (2008) The 15-deoxy-delta 12,14-prostaglandin J2 suppresses monocyte chemoattractant protein-1 expression in IFN-gamma-stimulated astrocytes through induction of MAPK phosphatase-1. J Immunol 181:8642–8649
Asakawa M, Takano H, Nagai T et al (2002) Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. Circulation 105:1240–1246
Tsuji T, Mizushige K, Noma T et al (2001) Pioglitazone improves left ventricular diastolic function and decreases collagen accumulation in prediabetic stage of a type II diabetic rat. J Cardiovasc Pharmacol 38:868–874
Khandoudi N, Delerive P, Berrebi-Bertrand I, Buckingham RE, Staels B, Bril A (2002) Rosiglitazone, a peroxisome proliferator-activated receptorgamma, inhibits the Jun NH(2)-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury. Diabetes 51:1507–1514
Liu HR, Tao L, Gao E et al (2004) Anti-apoptotic effects of rosiglitazone in hypercholesterolemic rabbits subjected to myocardial ischemia and reperfusion. Cardiovasc Res 62:135–144
Dormandy JA, Charbonnel B, Eckland DJA et al (2005) PRO active investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitazone clinical trial in macro vascular events): a randomised controlled trial. Lancet 366:1279–1289
Derosa G (2010) Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus: comparison with other oral antihyperglycaemic agents. Drugs 70:1945–1961
Acknowledgments
Grant support: Key Endocrine Laboratory of General Hospital and Animal Laboratory of Health Department of Tianjin Medical University. We thank Mr. WANG Yongming and Mrs. ZHANG Xinshi for helping with the care of the animals and technical aspects of this study.
Conflict of interest
M. Yuan, M. Qiu, J. Cui, X. Zhang, P. Zhang declare no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yuan, M., Qiu, M., Cui, J. et al. Protective effects of pioglitazone against immunoglobulin deposition on heart of streptozotocin-induced diabetic rats. J Endocrinol Invest 37, 375–384 (2014). https://doi.org/10.1007/s40618-013-0046-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40618-013-0046-5